Inovio doses first subject in Phase 2 Covid-19 vaccine trial
INO-4800 is an advanced prophylactic DNA vaccine candidate, designed to work against the activity of SARS-CoV-2, the virus…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
08 Dec 20
INO-4800 is an advanced prophylactic DNA vaccine candidate, designed to work against the activity of SARS-CoV-2, the virus…
08 Dec 20
Pfizer will leverage its extensive data and expertise, while PostEra its technology capabilities to advance the preclinical drug…
07 Dec 20
Sinovac will use the funding to further develop and expand the manufacturing capacity of its vaccine candidate CoronaVac
07 Dec 20
The UNITED study includes symptom tracking, in-home testing and in-home infusions to detect, intercept and provide early treatment…
04 Dec 20
Janssen’s BLA for amivantamab marks the first regulatory submission for the treatment of EGFR exon 20 insertion mutation-positive…
04 Dec 20
Orladeyo is the first once-daily oral therapy specifically designed to prevent attacks of HAE patients, by decreasing the…
03 Dec 20
The UK regulator MHRA has authorised the supply of mRNA-based Covid-19 vaccine for emergency use, with US FDA…
03 Dec 20
Gavreto is indicated for metastatic RET-mutant medullary thyroid cancer (MTC) in adult and paediatric patients, aged 12 years…
01 Dec 20
Forxiga is claimed to be the first approved SGLT2 inhibitor for chronic heart failure with reduced ejection fraction…
01 Dec 20
Dupixent is a fully-human monoclonal antibody discovered using Regeneron's original VelocImmune technology